Early discontinuation of tamoxifen: A lesson for oncologists

Cancer

Volumn 109, Issue 5, 2007, Pages 832-839

  Barron, Thomas I ^a   Connolly, Róisín M ^a   Bennett, Kathleen ^a   Feely, John ^a   Kennedy, M John ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Breast cancer; Compliance; Persistence; Tamoxifen

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGE FACTORS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT COMPLIANCE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33847373003     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22485     Document Type: Article

References (44)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
2. Bower H. Study backs tamoxifen for young women. BMJ. 1998;316:1553h.
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
4. ISPOR Medication Compliance & Persistence Special Interest Group. Available at URl: http://www.ispor.org/sigs/MCP_accomplishments.asp#defmition Accessed on July 17 2006.
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
6. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-574.
7. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963-070.
8. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529-1542.
9. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993-2000.
10. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19:931-942.
11. Fisher B, Bryant J, Dignam JJ, et al, Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141-4149.
12. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332;1125-1131.
13. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99:215-220.
14. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22:3309-3315.
15. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19:322-328.
16. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189-1197.
17. Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf. 2004;13:11-19.
18. Silliman RA, Guadagnoli E, Rakowski W, et al. Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol. 2002;20:2680-2688.
19. Perreault S, Biais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61:667-674.
20. Degli EE, Sturani A, Di MM, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16:439-444.
21. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23:1311-1320.
22. Fallowfield L, Atkins L, Catt S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17:205-210.
23. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59:97-102.
24. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42:2271-2276.
25. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602-606.
26. Trends in Irish cancer incidence 1994-2002, with projections to 2020. National Cancer Registry; 2006. Available at URL: http://www.ncri.ie/pubs/ pubfiles/proj_2020.pdf Accessed on July 20 2006.
27. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27-36.
28. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20:764-771.
29. Compas BE, Stoll MF, Thomsen AH, Oppedisano G, Epping-Jordan JE, Krag DN. Adjustment to breast cancer: age-related differences in coping and emotional distress. Breast Cancer Res Treat. 1999;54:195-203.
30. Ganz PA, Schag CC, Heinrich RL. The psychosocial impact of cancer on the elderly: a comparison with younger patients. J Am Geriatr Soc. 1985;33:429-435.
31. Maurice A, Howell A, Evans DG, O'neil AC, Scobie S. Predicting compliance in a breast cancer prevention trial. Breast J. 2006;12:446-450.
32. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366:2005-2011.
33. Hoagland AC, Morrow GR, Bennett JM, Carnrike CL Jr. Oncologists' views of cancer patient noncompliance. Am J Clin Oncol. 1983;6:239-244.
34. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
35. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer. 1990;65:17-22.
36. Goodwin JS, Zhang DD, Ostir GV Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc. 2004;52:106-111.
37. Hjerl K, Andersen EW, Keiding N, Mouridsen HT, Mortensen PB, Jorgensen T. Depression as a prognostic factor for breast cancer mortality. Psychosomatics. 2003;44:24-30.
38. Watson M, Haviland IS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet. 1999;354:1331-1336.
39. Watson M, Homewood J, Haviland J, Bliss JM. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. Eur J Cancer. 2005;41:1710-1714.
40. Mariani L, Quattrini M, Atlante M, Galati M, Barbati A, Giannarelli D. Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study. J Exp Clin Cancer Res. 2005;24:373-378.
41. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059-2063.
42. Barton DL, Loprinzi CL, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol. 2003;1:47-51.
43. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, cross-over study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006;12:114-122.
44. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005;CD000011.